CARCINOMA, NON-SMALL-CELL LUNG

This study tests a new drug, LY3537982, in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if the drug is safe and shrinks tumors. About 540 adults with lung, colon, endometrial, ovarian, pancreatic, or bile duct cancers …

This study is for people with advanced nonsquamous non-small cell lung cancer that has spread and no longer responds to standard immunotherapy or chemotherapy. Researchers are testing two antibody drug conjugates (ADCs) — targeted drugs that deliver treatment directly to cancer c…

This study tests an experimental drug called N17350 for adults with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into tumor lesions every two weeks for up to 12 weeks. Researchers aim to find the safest and most effective dos…

This large study is testing many different drug combinations, including the immunotherapy pembrolizumab and chemotherapy, for people with advanced non-small cell lung cancer. It aims to find which treatments work best for different tumor types. About 1065 adults with stage IV lun…

This study compares two treatments given before surgery for stages IB to III non-small cell lung cancer. One group gets immunotherapy (cemiplimab) plus chemotherapy, the other gets immunotherapy plus targeted radiation. After surgery, all participants continue immunotherapy for a…

This study tests whether adding two immunotherapy drugs (durvalumab and tremelimumab) to standard chemotherapy is safe and effective for people with HIV who have advanced non-small cell lung cancer. About 18 participants will receive the treatment, and researchers will monitor si…

This study tests whether adding the experimental drug olomorasib to standard immunotherapy can better control a certain type of lung cancer (KRAS G12C-mutant non-small cell lung cancer). About 700 adults whose cancer has been surgically removed or cannot be removed will receive e…

This study is for people with non-small cell lung cancer who had surgery but still had cancer cells left behind. It tests whether adding two drugs (sacituzumab and zimberelimab) after surgery can help keep the cancer from returning. About 129 participants will be split into three…

This early-stage study tests an experimental drug called PF-08046050 in people with advanced solid tumors that have come back or not improved with standard treatments. The drug is designed to attach to cancer cells and kill them. The main goal is to check safety and find the righ…

This study tests whether a new drug called THIO, given before an immunotherapy (cemiplimab), can help people with advanced non-small cell lung cancer whose disease has worsened after two prior treatments. About 300 adults will be randomly assigned to receive either the THIO-cemip…

This study tests whether adding the experimental drug LP-300 to standard chemotherapy can help people who have never smoked and have advanced lung cancer that stopped responding to targeted therapy. About 90 participants will receive either the drug combo or chemo alone. The goal…

This study tests a new gene therapy (quaratusugene ozeplasmid) added to the standard drug osimertinib for people with advanced EGFR-mutant non-small cell lung cancer that has stopped responding to osimertinib alone. About 158 adults with stage III or IV lung cancer will participa…

This study monitors adults with advanced ALK-positive non-small cell lung cancer who are starting brigatinib for the first time. Researchers will track side effects and measure how often tumors shrink or disappear. The goal is to confirm the drug's safety and effectiveness in eve…

This study is testing whether a team of doctors from different specialties can create better treatment plans for older adults (ages 60-90) with lung cancer. Each patient will get a personalized plan based on a full health assessment. The goal is to see if this team approach helps…

This early-stage trial tests a drug called sigvotatug vedotin, alone or with other medicines, in people with advanced solid tumors like lung, head and neck, or breast cancer. The goal is to find a safe dose and check for side effects. About 1,000 participants will join this study…

This trial tests a new drug called UCB4594, an antibody that targets a protein (HLA-G) found on many cancer cells. The goal is to see if it helps the immune system attack tumors. It is for people with advanced solid tumors (like lung, breast, or colon cancer) that have not respon…

This study tests a new experimental drug (PF-07934040) in people with advanced solid tumors that have a KRAS gene mutation, including certain lung, colon, and pancreatic cancers. The drug is taken as a pill twice a day, either alone or with other anti-cancer medicines given by IV…

This study tests whether adding an experimental vaccine (V940) to the standard immunotherapy drug pembrolizumab after surgery can help prevent lung cancer from returning. It includes 680 adults with stage II to IIIB non-small cell lung cancer whose tumors did not fully disappear …

This early-stage study is testing an experimental drug called JNJ-86974680, alone or with another drug (cetrelimab) and radiation, in people with advanced non-small cell lung cancer. The main goal is to find safe and tolerable doses. About 126 participants will take part.

This study looks at whether a simple blood test that tracks tumor DNA can help doctors decide if patients with advanced lung cancer need immunotherapy alone or combined with chemotherapy. About 108 adults with newly diagnosed stage IV non-small cell lung cancer and PD-L1 levels o…

This trial tests whether a combination of two drugs, vemurafenib and cobimetinib, can shrink or control rare cancers that have a specific BRAF V600 mutation. The drugs are already approved for melanoma, and researchers want to see if they help people with other cancer types, like…

This study tests whether adding a focused radiation boost (CyberKnife) after standard chemotherapy and radiation can help people with locally advanced non-small cell lung cancer live longer without the disease getting worse. About 42 adults with stage III lung cancer that cannot …

This early-stage trial tests an experimental drug, DM005, in about 136 people with advanced solid tumors like lung, head and neck, or other cancers that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see how the b…

This study tests whether adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific genetic subtype of advanced lung cancer (KRAS G12C) live longer without their cancer growing. About 630 adults who have not had prior treatment for …

This early-phase study tests an experimental drug called PF-08046876 in adults with advanced solid tumors (bladder, lung, head/neck, esophagus, or pancreatic cancer) that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to stick to cancer…

This early-phase study tests a new experimental drug called AZD9592, alone or with other cancer treatments, in people with advanced solid tumors (lung, head & neck, or colorectal cancers) that have not responded to standard therapy. The main goals are to check safety, find the ri…

This study tests a new drug called AST-201 in people with advanced solid tumors that have a protein called GPC3. The main goal is to check the drug's safety and find the right dose. About 70 adults with liver or lung cancer that has not responded to other treatments will take par…

This study tests whether adding an experimental drug (JNJ-90301900) to standard chemoradiation and a follow-up immunotherapy (durvalumab) can shrink tumors more effectively in people with stage III non-small cell lung cancer that cannot be removed by surgery. About 130 adults wil…

This study tests a new drug, BMS-986504, in people with advanced or spreading non-small cell lung cancer that has a specific genetic change (MTAP deletion) and has stopped responding to earlier treatments. About 130 participants will receive the drug alone to see if it shrinks tu…

This study tests whether a new experimental drug (PF-08634404) combined with chemotherapy works better than the current standard treatment (pembrolizumab plus chemo) for adults with advanced non-small cell lung cancer that has spread. About 1,410 participants will be randomly ass…

This study tests whether adding a new drug (Sigvotatug Vedotin) to standard immunotherapy (pembrolizumab) works better than immunotherapy alone for people with advanced non-small cell lung cancer that has high levels of PD-L1. About 714 adults with stage 3 or 4 lung cancer will t…

This study tests a combination of two drugs, amivantamab and olomorasib, in people with a specific type of advanced lung cancer (KRAS G12C mutation) that has spread. The goal is to find the best dose and see if the combo can shrink tumors or slow their growth. About 60 participan…

This early-stage study tests a new drug, PF-08046054/SGN-PDL1V, in people with advanced solid tumors that have spread or can't be removed. The drug is given alone or with pembrolizumab to see if it's safe and what side effects occur. About 714 participants with cancers like lung,…

This study tests a new treatment for people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer) that has spread to the lining of the brain and spinal cord (leptomeningeal metastasis) and has stopped responding to the drug osimertinib. The treatment combin…

This study tests a new medicine called PF-08634404 combined with other cancer drugs in people with advanced non-small cell lung cancer that has spread and cannot be removed by surgery. The goal is to see if the combination is safe and can shrink tumors. About 162 adults will rece…

This study follows 800 adults in China who have had surgery for early-stage ALK-positive lung cancer and are taking alectinib to prevent the cancer from coming back. Researchers want to see how long patients stay cancer-free in real-world settings. The goal is to understand if th…

This study tests a new drug called LY4175408 in people with advanced lung, endometrial, or breast cancer that has spread. The drug is designed to target and kill cancer cells while sparing healthy ones. The goal is to check safety, how the drug moves through the body, and whether…

This study compares a new drug, BAT3306, to the approved drug Keytruda in people with stage IB-IIIA non-small cell lung cancer whose tumors were completely removed by surgery. The goal is to see if BAT3306 works similarly in the body as an additional treatment after surgery. Abou…

This study tests whether adding a new targeted drug (LY3537982) to standard treatments helps people with a specific genetic subtype of advanced non-small cell lung cancer (KRAS G12C mutation). About 1,264 participants will receive either the new drug combo or standard therapy. Th…

This study tests two drug combinations for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). One group gets a new drug (amivantamab) plus a targeted pill (lazertinib) as their first treatment. Another group gets amivantamab with c…

This study tests a subcutaneous (under-the-skin) form of the drug amivantamab in people with advanced EGFR-mutated non-small cell lung cancer. About 520 participants will receive the drug in different combinations to see if it shrinks tumors and how safe it is. The goal is to con…

This study is for people with stage IV non-small cell lung cancer who have not had any prior treatment. It tests whether adding new experimental drugs to the standard immunotherapy (pembrolizumab) with or without chemotherapy can shrink tumors or control the disease better. About…

This study compares a new drug, rilvegostomig, to the current standard treatment, pembrolizumab, for people with advanced non-small cell lung cancer that has high levels of PD-L1. The goal is to see if the new drug works better at helping people live longer or stopping the cancer…

This study tests an inhaled form of the drug azacytidine, given alongside standard chemotherapy and immunotherapy, for people with early-stage non-small cell lung cancer that can be removed by surgery. The goal is to find the safest and most effective dose and see if this combina…

This pilot study tests whether giving a higher dose of proton therapy to the lung tumor is safe for people with stage III non-small-cell lung cancer who are also receiving chemotherapy. About 87 participants will receive the higher dose during the same number of treatment visits …

This study tests a new drug called LY4170156 in people with advanced solid tumors, such as ovarian, lung, and breast cancers. The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has two parts: first to find the safest dose, then to see how w…

This study compares standard bronchoscopy (a lung scope procedure) with and without a special laser imaging tool called nCLE. The goal is to see if nCLE helps doctors place the biopsy needle more accurately, leading to a clear diagnosis more often. About 208 adults with suspiciou…

This study is testing a new supportive care program called POISE for people with stage IV non-small cell lung cancer who are on targeted therapy. The program includes four visits with a specially trained palliative care clinician to help patients cope with uncertainty and manage …

This study follows 7,500 people with newly diagnosed non-small cell lung cancer to see how quickly they get biomarker testing and whether the results guide their first treatment. Researchers want to find out what delays testing, such as tissue issues or insurance problems, so the…

This study is a registry that collects information from 3,750 adults with lung cancer across 21 hospitals in Algeria. Researchers will track patient details, tumor types, treatments, and outcomes over time. The goal is to understand how lung cancer is diagnosed and managed in rea…

This study observes about 380 people with a common type of advanced lung cancer caused by an EGFR gene change. Participants receive amivantamab as part of their normal care. Researchers will track how long people stay on treatment and how long the cancer is controlled, aiming to …

This study is collecting health information and biological samples from 730 adults newly diagnosed with lung cancer. Researchers aim to track how patients respond to treatments in real-world settings, including those often excluded from clinical trials. The goal is to better unde…